PATENT ABSTRACTS 225

the cytopathic effect of HTLV-III. The ATH8 T- cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or in- hibit HTLV-III or related cytopathic retroviruses.

4704362

R E C O M B I N A N T C L O N I N G V E H I C L E M I C R O B I A L

P O L Y P E P T I D E E X P R E S S I O N

polysaccharide-like-antigenic substance (TPS) obtained by removing lipids and protein from a differential centrifugation sediment of a saline suspension of the mitochondrial fraction of cancer tissue, e.g. from carcinoma, fibrosar- coma, lymphoma, or melanoma: and (b) deoxy- ribonucleic acid (DNA) derived from the nuclear fraction of malignant tumor tissue; or (c) the un- tritiated form of the glycoprotein polysaccharide-like antigenic substance (TPS) described in (a) above.

Keiich Itakura, Arthur Riggs assigned to Gene- ntech Inc

The Specification discloses: 1. Recombinant microbial cloning vehicles comprising hetero- logous DNA coding for the expression of mam- malian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter in- corporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA; 2. Cloning vehicles coding for the microbial expres- sion of a protein variously comprising (a) a poly- peptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising anti- bodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired poly- peptide product and additional protein from which the desired product may be cleaved; and 3. Methods of preparing synthetic structural genes coding for the expression of mammalian poly- peptides in microbial cloning systems.

4705687

T R E A T M E N T O F A U T O I M M U N E D I S E A S E S S U C H A S

R H E U M A T O I D A R T H R I T I S W I T H S U P P R E S S O R F A C T O R

Catherine Y Lau, Unionviile, Canada assigned to Ortho Pharmaceutical (Canada) Ltd

Method of treating autoimmune diseases such as rheumatoid arthritis by administration of a sup- pressor factor obtained in the supernatant of a human cell line. A particular human cell line is CEM which has survived treatment with 6- thioguanine.

4705750

4705677

I M M U N I Z A T I O N

Jack Makari

Disclosed is a method of providing immuno- prophylaxis as well as malignant tumor immuno-therapy by administering a malignant- tumor-immunization and recession-provoking antigenic agent of malignant tumor tissue source to a living subject in an effective dosage and regimen to develop a sutticiently high level of defense against malignant tumor incipience, or to retard such tumor development and/or pro- voke its recession. The malignant-tumor- immunization and recession-provoking antigenic agent or tumor tissue source is a com- bination of: (a) the tritiated form of glyeoprotein

P R O M O T E R P L A S M I D C O N T A I N I N G T H E P R O M O T E R

A N D U S E T H E R E O F I N T R A N S F O R M I N G B A C I L L U S

Kikuchi Masakazu, Nakahama Kazuo, Toyono, Japan assigned to Takeda Chemical Industries Ltd

A novel recombinant DNA containing the base sequence shown in FIG. I or a portion thereof which exhibits promoter activity. The base sequence exhibiting a potent promoter activity is obtained from the chromosomal DNA of strain Bacillus by, for example, cloning with a cloning vector. By growing a transformant of Bacillus transformed with the recombinant DNA car- lying a peptide encoding nucleotide, the desired peptide may be produced.